Last reviewed · How we verify
NCT05386641
Risk Factors for Shoulder Joint Motion Restriction
trial testing measurement of tissue stiffness (N/m) in Breast Cancer Survivors in 72 participants. Status unknown.
15 August 2023
Quick facts
| Lead sponsor | Istanbul Medeniyet University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 72 |
| Start date | 15 August 2022 |
| Primary completion | 15 August 2023 |
| Estimated completion | 15 February 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- measurement of tissue stiffness (N/m)
- measurement of passive muscle tone (Hz)
- measurement of creep of tissue
- measurement of the range of shoulder joint motion
- measurement of skin temperature
- measurement of pain
- measurement of pain pressure threshold
- measurement of grip strength
Conditions studied
- Breast Cancer Survivors — all drugs for Breast Cancer Survivors →
Sponsor
Istanbul Medeniyet University
Who can join
Adults 30 to 60, female only, with Breast Cancer Survivors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In breast cancer patients, limitation of shoulder joint movement may occur following cancer treatment. Shoulder limitation causes a significant decrease in the patient's participation in activities of daily living. The aim of the study is to define these limitations, to evaluate in detail all the structures that cause the problem, and to determine the causes of the limitations in patients with shoulder joint movement limitation developed after breast cancer survivors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05386641
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Survivors
Currently open trials in the same condition.
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07334626 — Impact of Pilates Exercises on Bone Mineral Density in Breast Cancer Survivors Receiving Hormonal Therapy · NA · recruiting
- NCT07280143 — The Development of MASLD Among Survivors of Breast or Colorectal Cancer · recruiting
- NCT07214883 — UCF MammoChat: Image Repository · recruiting
- NCT07284030 — Psychoeducation and Well-Being After Breast Cancer · NA · recruiting
Other Istanbul Medeniyet University trials
Trials by the same sponsor.
- NCT07478380 — Transcutaneous pO₂ Monitoring in PICU · recruiting
- NCT07368244 — Turkish Translation and Content Validity of the Nottwil Environmental Factors Inventory (NEFI) in Persons With Spinal Co · recruiting
- NCT07179731 — Comparison of the Effects of External Oblique Intercostal Plane Block, Subcostal Transverse Abdominis Plane Block, and T · NA · not yet recruiting
- NCT07241455 — Validity of the Children's Chelsea Critical Care Physical Assessment Tool (cCPAx-TR) in Turkish Pediatric Intensive Care · completed
- NCT07426497 — Osteopathic Manual Therapy vs Ganglion Impar Block for Chronic Coccydynia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05386641 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul Medeniyet University
- Last refreshed: 31 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05386641.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing